High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
| Autor: | Zwierenga, Fenneke, van Veggel, Bianca, Hendriks, Lizza E.L., Hiltermann, T. Jeroen N., Hiddinga, Birgitta I., Hijmering Kappelle, Lucie B.M., ter Elst, Arja, Hashemi, Sayed M.S., Dingemans, Anne-Marie C., van der Leest, Cor, de Langen, Adrianus J., van den Heuvel, Michel M., van der Wekken, Anthonie J. |
|---|---|
| Zdroj: | In Lung Cancer August 2022 170:133-140 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect